PriceTargets.com logo

Hikma Pharmaceuticals - HIK Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 2,416
  • Forecasted Upside: 51.95%
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,590 As of 12/4/2025 12:59 PM ET
▲ +10 (0.63%)

This chart shows the closing price for HIK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hikma Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HIK

Analyst Price Target is GBX 2,416
▲ +51.95% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Hikma Pharmaceuticals in the last 3 months. The average price target is GBX 2,416, with a high forecast of GBX 2,850 and a low forecast of GBX 2,170. The average price target represents a 51.95% upside from the last price of GBX 1,590.

This chart shows the closing price for HIK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Hikma Pharmaceuticals. This rating has held steady since May 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/7/2025Peel HuntReiterated RatingBuyGBX 2,170
11/7/2025JPMorgan Chase & Co.Lower TargetOverweightGBX 2,500 ➝ GBX 2,400
11/7/2025Jefferies Financial GroupReiterated RatingBuyGBX 2,360
11/6/2025Berenberg BankLower TargetBuyGBX 2,510 ➝ GBX 2,300
10/16/2025Berenberg BankLower TargetBuyGBX 2,560 ➝ GBX 2,510
8/12/2025Deutsche Bank AktiengesellschaftLower TargetBuyGBX 3,100 ➝ GBX 2,850
8/8/2025JPMorgan Chase & Co.Lower TargetOverweightGBX 2,600 ➝ GBX 2,500
8/7/2025Jefferies Financial GroupReiterated RatingBuyGBX 2,600
3/10/2025Berenberg BankReiterated RatingBuyGBX 2,560
3/7/2025JPMorgan Chase & Co.Reiterated RatingOverweight
1/29/2025Berenberg BankBoost TargetBuyGBX 2,400 ➝ GBX 2,560
9/2/2024Berenberg BankUpgradeBuyGBX 2,100 ➝ GBX 2,400
8/12/2024Berenberg BankBoost TargetHoldGBX 2,000 ➝ GBX 2,100
6/18/2024Deutsche Bank AktiengesellschaftReiterated RatingBuyGBX 2,750
5/7/2024BarclaysReiterated RatingEqual WeightGBX 2,000
4/25/2024Berenberg BankReiterated RatingHoldGBX 2,000
4/8/2024BarclaysReiterated RatingEqual WeightGBX 2,000
2/26/2024Berenberg BankBoost TargetHoldGBX 1,960 ➝ GBX 2,000
11/13/2023Royal Bank Of CanadaReiterated RatingSector PerformGBX 2,150
10/16/2023JPMorgan Chase & Co.Reiterated RatingOverweight
10/3/2023CitigroupReiterated RatingBuy
7/12/2023BarclaysBoost TargetEqual WeightGBX 1,700 ➝ GBX 1,800
5/22/2023Jefferies Financial GroupBoost TargetBuyGBX 2,080 ➝ GBX 2,125
5/3/2023BarclaysReiterated RatingEqual WeightGBX 1,700
4/12/2023Jefferies Financial GroupReiterated RatingBuyGBX 2,080
3/9/2023JPMorgan Chase & Co.Reiterated RatingOverweightGBX 2,100
3/1/2023Royal Bank Of CanadaBoost TargetOutperformGBX 1,750 ➝ GBX 1,950
2/24/2023Berenberg BankBoost TargetHoldGBX 1,440 ➝ GBX 1,740
2/24/2023BarclaysBoost TargetEqual WeightGBX 1,650 ➝ GBX 1,700
2/14/2023JPMorgan Chase & Co.Reiterated RatingOverweight
1/31/2023CitigroupReiterated RatingBuyGBX 1,920
12/5/2022BarclaysReiterated RatingEqual WeightGBX 1,350
12/1/2022Berenberg BankReiterated RatingHoldGBX 1,440
11/3/2022Berenberg BankReiterated RatingHoldGBX 1,440
11/1/2022BarclaysReiterated RatingEqual WeightGBX 1,400
10/4/2022Berenberg BankReiterated RatingHoldGBX 1,440
9/30/2022BarclaysReiterated RatingEqual WeightGBX 1,750
8/31/2022BarclaysReiterated RatingEqual WeightGBX 1,750
8/11/2022JPMorgan Chase & Co.Lower TargetNeutralGBX 1,900 ➝ GBX 1,760
8/5/2022BarclaysDowngradeEqual WeightGBX 2,250 ➝ GBX 1,750
8/2/2022BarclaysReiterated RatingOverweightGBX 2,250
7/19/2022BarclaysLower TargetOverweightGBX 2,500 ➝ GBX 2,250
7/4/2022BarclaysReiterated RatingOverweightGBX 2,500
6/1/2022BarclaysReiterated RatingOverweightGBX 2,500
5/25/2022JPMorgan Chase & Co.DowngradeNeutralGBX 2,900 ➝ GBX 1,900
5/24/2022BarclaysReiterated RatingOverweightGBX 2,500
5/11/2022Morgan StanleyReiterated RatingEqual Weight
5/9/2022BarclaysReiterated RatingOverweightGBX 2,800
4/29/2022BarclaysReiterated RatingOverweightGBX 2,800
4/14/2022BarclaysReiterated RatingOverweightGBX 2,800
4/4/2022BarclaysReiterated RatingOverweightGBX 2,800
3/15/2022BarclaysReiterated RatingOverweightGBX 2,800
3/7/2022BarclaysReiterated RatingOverweightGBX 2,800
3/3/2022Morgan StanleyDowngradeEqual WeightGBX 2,800 ➝ GBX 2,300
2/21/2022BarclaysReiterated RatingOverweightGBX 2,800
2/9/2022Morgan StanleyReiterated RatingOverweight
2/9/2022BarclaysLower TargetOverweightGBX 3,000 ➝ GBX 2,800
1/24/2022BarclaysReiterated RatingOverweightGBX 7,000
1/17/2022JPMorgan Chase & Co.Reiterated RatingOverweight
1/4/2022JPMorgan Chase & Co.Reiterated RatingOverweight
12/17/2021BarclaysReiterated RatingOverweightGBX 3,000
11/4/2021BarclaysReiterated RatingOverweightGBX 3,000
11/4/2021Peel HuntReiterated RatingHoldGBX 2,460
11/4/2021Peel HuntReiterated RatingHoldGBX 2,460
11/1/2021CitigroupReiterated RatingBuyGBX 2,880
10/20/2021BarclaysBoost TargetOverweightGBX 2,900 ➝ GBX 3,000
9/2/2021BarclaysBoost TargetOverweightGBX 2,800 ➝ GBX 2,900
7/19/2021BarclaysReiterated RatingOverweightGBX 2,800
5/6/2021BarclaysReiterated RatingOverweightGBX 2,800
2/1/2021CitigroupReiterated RatingBuy
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 4 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 4 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 3 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 7 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 7 very positive mentions
  • 21 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Hikma Pharmaceuticals logo
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing facilities, 9 R&D centres and 9,500 employees worldwide.
Read More

Today's Range

Now: GBX 1,590
Low: 1,575
High: 1,600

50 Day Range

MA: GBX 1,698.95
Low: 1,522
High: 1,851

52 Week Range

Now: GBX 1,590
Low: 1,522
High: 2,360

Volume

279,019 shs

Average Volume

1,915,897 shs

Market Capitalization

£3.52 billion

P/E Ratio

9.52

Dividend Yield

4.09%

Beta

0.41

Frequently Asked Questions

What sell-side analysts currently cover shares of Hikma Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Hikma Pharmaceuticals in the last twelve months: Berenberg Bank, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., and Peel Hunt.
View the latest analyst ratings for HIK.

What is the current price target for Hikma Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Hikma Pharmaceuticals in the last year. Their average twelve-month price target is GBX 2,416, suggesting a possible upside of 51.9%. Deutsche Bank Aktiengesellschaft has the highest price target set, predicting HIK will reach GBX 2,850 in the next twelve months. Peel Hunt has the lowest price target set, forecasting a price of GBX 2,170 for Hikma Pharmaceuticals in the next year.
View the latest price targets for HIK.

What is the current consensus analyst rating for Hikma Pharmaceuticals?

Hikma Pharmaceuticals currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HIK will outperform the market and that investors should add to their positions of Hikma Pharmaceuticals.
View the latest ratings for HIK.

What other companies compete with Hikma Pharmaceuticals?

Other companies that are similar to Hikma Pharmaceuticals include Indivior, HUTCHMED, Allergy Therapeutics, Amryt Pharma and Alliance Pharma. Learn More about companies similar to Hikma Pharmaceuticals.

How do I contact Hikma Pharmaceuticals' investor relations team?

Hikma Pharmaceuticals' physical mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company's listed phone number is +44-20-73992760. The official website for Hikma Pharmaceuticals is www.hikma.com. Learn More about contacing Hikma Pharmaceuticals investor relations.